Infinity finds new taker for duvelisib

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) granted Verastem Inc. (NASDAQ:VSTM) exclusive, worldwide rights to develop and commercialize duvelisib (IPI-145), an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma.

The companies expect data in 1H17 from the ongoing Phase III DUO trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukemia (CLL). The study is comparing duvelisib with approved therapy Arzerra ofatumumab, with a primary endpoint of progression-free survival (PFS)...